Chemotherapy-Induced Anemia Pipeline Insights Report, 2024 Featuring Analysis of Roxadustat (FibroGen), SPP-003 (SBI Pharmaceuticals), and More
May 31, 2024 06:26 ET
|
Research and Markets
Dublin, May 31, 2024 (GLOBE NEWSWIRE) -- The "Chemotherapy-Induced Anemia - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides...
FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference
March 26, 2024 07:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, March 26, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Thane Wettig, Chief Executive Officer, will participate in a corporate presentation at the 23rd...
FibroGen To Report Third Quarter 2019 Financial Results on Monday, November 11, 2019
November 04, 2019 07:00 ET
|
FibroGen, Inc
SAN FRANCISCO, Nov. 04, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), today announced that financial results for the third quarter 2019 will be released after market on Monday, November...
FibroGen Announces Initiation of Phase 2 Clinical Trial of Roxadustat for the Treatment of Anemia in Cancer Patients Receiving Chemotherapy
September 26, 2019 07:00 ET
|
FibroGen, Inc
SAN FRANCISCO, Sept. 26, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced first patient dosed in the company’s Phase 2 clinical study of roxadustat, a first-in-class...